BOX WARNING
Drug Dependence
Ritalin LA should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.
|
| |
RITALIN LA SUMMARY
Methylphenidate hydrochloride is a central nervous system (CNS) stimulant.
Ritalin LA® (methylphenidate hydrochloride) extended-release capsules is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
|
|
NEWS HIGHLIGHTS
Published Studies Related to Ritalin LA (Methylphenidate)
The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1
Trial. [2015]
advanced cancer... CONCLUSION: MPH does not improve fatigue in the population of patients with
Drug-specific laterality effects on frontal lobe activation of atomoxetine and
methylphenidate in attention deficit hyperactivity disorder boys during working
memory. [2014]
CONCLUSIONS: The study shows both shared and drug-specific effects. ATX
Long-term (1 year) safety and efficacy of methylphenidate modified-release
long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity
disorder: a 26-week, flexible-dose, open-label extension to a 40-week,
double-blind, randomised, placebo-controlled core study. [2014]
26-week, open-label extension phase of the same study (NCT01338818)... CONCLUSIONS: In adult patients with ADHD, use of MPH-LA up to 1 year continued to
Effect of extended-release dexmethylphenidate and mixed amphetamine salts on
sleep: a double-blind, randomized, crossover study in youth with
attention-deficit hyperactivity disorder. [2014]
measures of sleep... CONCLUSIONS: Higher stimulant doses were associated with reduced sleep duration
A randomized, double-blind, placebo-controlled, parallel-group study to evaluate
the efficacy and safety of osmotic-controlled release oral delivery system
methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in
Japan. [2014]
attention-deficit/hyperactivity disorder (ADHD)... CONCLUSIONS: OROS MPH in a dose range of 18-72 mg once daily was effective and
Clinical Trials Related to Ritalin LA (Methylphenidate)
Methylphenidate Study in Breast or Gastrointestinal Cancer Patients [Terminated]
The goal of this clinical research study is to see if the drug OROS Methylphenidate HCl
(Concerta) can help to control fatigue in patients with breast, gastrointestinal, lymphoma,
myeloma or lung cancer who are going through chemotherapy or hormonal treatment or have
completed chemotherapy or hormonal treatment in the last 12 months. The safety of this drug
will also be studied. Another goal of the study is to see how certain cytokines change
while patients undergo chemotherapy or hormonal treatment.
Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD [Completed]
Methylphenidate may improve sleep in children with ADHD. By leaving Daytrana
(methylphenidate) patch for a longer time then 9 hours, many children report short sleep
latencies and better quality of sleep.
The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. [Terminated]
This project aims to determine if methylphenidate can improve deficits in attention and
symptoms of orthostatic hypotension, two common non-motor symptoms, in patients with
Parkinson's Disease. This project also seeks to evaluate the effect of methylphenidate on
postural control in these patients, a debilitating motor symptom that places patients at an
increased risk of falling. This study will build on existing data to support a new
indication for the use of methylphenidate in Parkinson's Disease. Using standard and
objective evaluations, this study will quantify the effect of methylphenidate at two doses
on attention levels, orthostatic hypotension, and measures of postural control. Phase I of
the study will compare methylphenidate 10mg three times daily to placebo and Phase II of the
study, for those tolerating the lower dose in Phase I, will compare methylphenidate 20mg
three times daily to placebo. By incorporating two different doses, the study also seeks to
determine if any improvements are dose-related. Secondary endpoints will include safety
assessments (adverse event monitoring and vital signs) performed every 30 minutes following
supervised drug administration. Visual analog scales will be presented to each participant
before treatment and following the final dose of each treatment to assess changes in
fatigue. A secondary task will be added to postural tests to assess the influence of
cognitive processes. It is hypothesized that methylphenidate will demonstrate a significant
beneficial effect on all outcomes. It is projected that objective improvements will be
observed following treatment with methylphenidate at both doses (10 and 20mg three time
daily) when compared to placebo. It is further hypothesized that the effects will be
dose-related and therefore more profound with higher doses.
A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers [Completed]
Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study [Recruiting]
Traditionally, memory impairments in the elderly population are treated using cholinesterase
inhibitors, although impairments remain after treatment. Dopamine (DA) is also involved in
cognition and is especially of interest in healthy ageing because of the role in processing
speed and cognitive control. To what extent dopamine treatment improves memory and attention
in older impaired individuals is unknown. However, such an effect is conceivable because of
the close relationship between memory and attention in aging and since improved processing
speed and cognitive control may lead to improved memory.
The investigators aim to examine, in the impaired older population, whether a treatment
using methylphenidate, a DA re-uptake inhibitor that enhances DA, improves attention and
memory. The study will be conducted according to a cross-sectional, double-blind,
placebo-controlled, 2-way cross-over design. 20 male and female patients with Mild Cognitive
Impairment (MCI), amnestic type, aged above 60 years of age; 20 male and female patients
with MCI, non-amnestic type, will be recruited from the Orbis Medical Centre. Participants
will be treated once with 20 mg methylphenidate (MPH) and once with placebo. All medications
will be administered orally with a capsule. The treatment order will be established by
counterbalancing.
Reports of Suspected Ritalin LA (Methylphenidate) Side Effects
Drug Ineffective (13),
Somnolence (9),
Agitation (8),
Anxiety (8),
Insomnia (8),
Fatigue (7),
Aggression (7),
Loss of Consciousness (6),
Dizziness (6),
Abnormal Behaviour (6), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Ritalin LA has an overall score of 8. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
| | Ritalin LA review by 41 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | ADHD |
| Dosage & duration: | | 30mg taken 1 for the period of 1 yr |
| Other conditions: | | Depression |
| Other drugs taken: | | Cymbalta | | |
Reported Results |
| Benefits: | | This medication enabled me to think clearly. My thought processes were more coherent. It assisted me in concentrating and therefore I was able to complete tasks --- finally had follow-thru! I was able to manage my time better. |
| Side effects: | | This medication caused me to be nervous, tremble and I became slightly irritable. |
| Comments: | | n/a |
|
|
|
Page last updated: 2015-08-10
|
